CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU,
China , July 25, 2024 /PRNewswire/ --
Harbour BioMed (the "Company"; HKEX: 02142), a global
biopharmaceutical company committed to the discovery, development,
and commercialization of novel antibody therapeutics focusing on
oncology and immunology, announced today that the Company will
release the latest clinical data on its first-in-class fully human
anti-B7H7/HHLA2 monoclonal antibody, HBM1020, for advanced solid
tumors at the ESMO Congress 2024, taking place from September 13-17, 2024, in Barcelona, Spain.
HBM1020, generated from Harbour Mice® H2L2 transgenic
mice platform, is the first therapeutic monoclonal antibody against
B7H7/HHLA2 to have entered clinical development globally. Data from
the dose-escalation study of a phase I, multi-center, open-label
trial (NCT05824663) demonstrated the promising safety and
tolerability profiles of HBM1020 in patients with advanced solid
tumors.
The findings will be displayed as a poster presentation during
the ESMO Congress 2024. Details of the presentation are as
follows:
Title: Ph I Dose-Escalation Study of HBM1020, a
Novel Anti-B7H7 Antibody in Patients with Advanced Solid Tumors
Presentation Number: 1010P
Onsite Poster Display Date: Saturday, September 14, 2024
Speaker: Jason Henry
All accepted abstracts will be published online on the ESMO
website.
About HBM1020
HBM1020 is a first-in-class fully human monoclonal antibody
generated from Harbour Mice® H2L2 transgenic mice
platform, targeting B7H7/HHLA2.
B7H7, also known as HHLA2, is a novel immune modulatory molecule
belonging to the B7 family. The B7 family is of central importance
in regulating the T-cell response, making these pathways very
attractive in cancer immunotherapy. Most of the validated targets
in immune-oncology so far are related to B7 family, including
PD-(L)1, and CTLA-4. The therapies against B7 family targets have
already shifted the paradigm for cancer therapy with outstanding
clinical benefits. As a newly discovered member of the B7 family,
B7H7 expression is found non-overlapping with PD-L1 expression in
multiple tumor types, which indicates an alternative immune evasion
pathway besides PD-(L)1. In PD-L1 negative/ refractory patients,
B7H7 potentially plays a critical role for tumor cells to escape
immune surveillance. HBM1020 can enhance anti-tumor immunity by
blocking the novel immune checkpoint target. Preclinical data
demonstrated its immune activation and anti-tumor functional
activities.
With its innovative biology mechanisms, HBM1020 presents a novel
anti-tumor therapeutics complementary to PD-(L)1 therapeutics to
patients, especially for PD-L1 negative/refractory patients.
About Harbour BioMed
Harbour BioMed (HKEX: 02142) is a global biopharmaceutical
company committed to the discovery, development, and
commercialization of novel antibody therapeutics focusing on
immunology and oncology. The Company is building its robust
portfolio and differentiated pipeline through internal R&D
capability, collaborations with co-discovery and co-development
partners, and select acquisitions.
The proprietary antibody technology platforms Harbour
Mice® generates fully human monoclonal antibodies
in two heavy and two light chains (H2L2) format, as well as heavy
chain only (HCAb) format. Building upon the HCAb antibodies, the
HCAb-based immune cell engagers (HBICE®) bispecific
antibody technology is capable of delivering tumor-killing effects
unachievable by traditional combination therapies. Integrating
Harbour Mice®, and HBICE® with a single
B cell cloning platform, our antibody discovery engine is highly
unique and efficient for the development of next-generation
therapeutic antibodies. For further information, please refer
to www.harbourbiomed.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/harbour-biomed-to-present-the-latest-progress-of-the-first-in-class-fully-human-anti-b7h7hhla2-monoclonal-antibody-hbm1020-at-the-esmo-congress-2024-302207269.html
SOURCE Harbour BioMed